Ajay K Kakkar

Summary

Affiliation: Thrombosis Research Institute
Country: UK

Publications

  1. ncbi request reprint Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy
    Ajay K Kakkar
    Centre for Surgical Sciences, St Bartholomew s and The London Hospitals Medical School, University of London, UK
    Thromb Haemost 94:867-71. 2005
  2. ncbi request reprint Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism
    Victor F Tapson
    Division of Pulmonary and Critical Care, Box 31175, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
    Chest 132:936-45. 2007
  3. doi request reprint Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
    Ajay K Kakkar
    Barts and the London School of Medicine and Dentistry, London, UK
    Lancet 372:31-9. 2008
  4. doi request reprint Perturbation of the heparin/heparin-sulfate interactome of human breast cancer cells modulates pro-tumourigenic effects associated with PI3K/Akt and MAPK/ERK signalling
    Yunliang Chen
    Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, London SW3 6LR, UK
    Thromb Haemost 109:1148-57. 2013
  5. ncbi request reprint Low-molecular-weight heparin and survival in patients with malignant disease
    Ajay K Kakkar
    Centre for Surgical Sciences, Institute of Cancer, Barts and the London School of Medicine and Dentistry, London, EC1 UK
    Cancer Control 12:22-30. 2005
  6. ncbi request reprint Thrombosis and cancer: implications beyond Trousseau
    A K Kakkar
    Centre for Surgical Sciences, St Bartholomew s and The London Hospitals Medical School, Thrombosis Research Institute, London, UK
    J Thromb Haemost 2:1261-2. 2004
  7. ncbi request reprint Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)
    Ajay K Kakkar
    Department of Surgical Oncology and Technology, and Cancer Research UK Laboratories, Imperial College, London, United Kingdom
    J Clin Oncol 22:1944-8. 2004
  8. doi request reprint Prevention of venous thromboembolism in the cancer surgical patient
    Ajay K Kakkar
    Barts and London School of Medicine and Dentistry and Thrombosis Research Institute, London, United Kingdom
    J Clin Oncol 27:4881-4. 2009
  9. ncbi request reprint Antithrombotics and cancer: evidence for survival benefit
    Ajay K Kakkar
    Hammersmith Hospital Imperial College, Thrombosis Research Institute, London, UK
    Pathophysiol Haemost Thromb 33:67. 2003
  10. ncbi request reprint An expanding role for antithrombotic therapy in cancer patients
    Ajay K Kakkar
    Department of Surgical Oncology and Technology, Imperial College, Hammersmith Hospital, Du Cane Road, W12 0NN, London, UK
    Cancer Treat Rev 29:23-6. 2003

Detail Information

Publications53

  1. ncbi request reprint Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy
    Ajay K Kakkar
    Centre for Surgical Sciences, St Bartholomew s and The London Hospitals Medical School, University of London, UK
    Thromb Haemost 94:867-71. 2005
    ..0.71% [120/16954], RR, 4.54 [95% CI, 3.59, 5.76], p=0.0001), as were blood loss (p<0.0001), and transfusion requirements (p<0.0001). Prevention of venous thromboembolism in cancer surgical patients remains a clinical challenge...
  2. ncbi request reprint Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism
    Victor F Tapson
    Division of Pulmonary and Critical Care, Box 31175, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
    Chest 132:936-45. 2007
    ..Our aim was to characterize the clinical practices for VTE prophylaxis in acutely ill hospitalized medical patients enrolled in the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE)...
  3. doi request reprint Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
    Ajay K Kakkar
    Barts and the London School of Medicine and Dentistry, London, UK
    Lancet 372:31-9. 2008
    ..Our aim was to compare the use of rivaroxaban for extended thromboprophylaxis with short-term thromboprophylaxis with enoxaparin...
  4. doi request reprint Perturbation of the heparin/heparin-sulfate interactome of human breast cancer cells modulates pro-tumourigenic effects associated with PI3K/Akt and MAPK/ERK signalling
    Yunliang Chen
    Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, London SW3 6LR, UK
    Thromb Haemost 109:1148-57. 2013
    ..In conclusion, the interaction between cell surface HPSGs and innate heparin/HS interactomes makes a significant contribution to the tumourigenicity...
  5. ncbi request reprint Low-molecular-weight heparin and survival in patients with malignant disease
    Ajay K Kakkar
    Centre for Surgical Sciences, Institute of Cancer, Barts and the London School of Medicine and Dentistry, London, EC1 UK
    Cancer Control 12:22-30. 2005
  6. ncbi request reprint Thrombosis and cancer: implications beyond Trousseau
    A K Kakkar
    Centre for Surgical Sciences, St Bartholomew s and The London Hospitals Medical School, Thrombosis Research Institute, London, UK
    J Thromb Haemost 2:1261-2. 2004
  7. ncbi request reprint Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)
    Ajay K Kakkar
    Department of Surgical Oncology and Technology, and Cancer Research UK Laboratories, Imperial College, London, United Kingdom
    J Clin Oncol 22:1944-8. 2004
    ..Furthermore, it has been suggested that low molecular weight heparin therapy may prolong survival in patients with cancer. The primary aim of this study was to assess survival at 1 year of patients with advanced cancer...
  8. doi request reprint Prevention of venous thromboembolism in the cancer surgical patient
    Ajay K Kakkar
    Barts and London School of Medicine and Dentistry and Thrombosis Research Institute, London, United Kingdom
    J Clin Oncol 27:4881-4. 2009
    ..These agents are recommended for the prevention of thromboembolic disease during hospital stay. For selected high-risk populations, extended thromboprophylaxis into the postdischarge period is also recommended...
  9. ncbi request reprint Antithrombotics and cancer: evidence for survival benefit
    Ajay K Kakkar
    Hammersmith Hospital Imperial College, Thrombosis Research Institute, London, UK
    Pathophysiol Haemost Thromb 33:67. 2003
  10. ncbi request reprint An expanding role for antithrombotic therapy in cancer patients
    Ajay K Kakkar
    Department of Surgical Oncology and Technology, Imperial College, Hammersmith Hospital, Du Cane Road, W12 0NN, London, UK
    Cancer Treat Rev 29:23-6. 2003
    ....
  11. doi request reprint Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients
    Ajay K Kakkar
    Barts and the London School of Medicine and Dentistry, London, United Kingdom
    Ann Surg 251:330-8. 2010
    ..To evaluate venous thromboembolism (VTE) risk in patients who underwent a major operation, including the use of, and factors influencing, American College of Chest Physicians-recommended types of VTE prophylaxis...
  12. ncbi request reprint What is the role for antithrombotics in cancer care? Interactive session with panel discussion
    Ajay K Kakkar
    Imperial College, London, UK
    Cancer Treat Rev 28:157-9. 2002
  13. doi request reprint Low-molecular-weight heparin and mortality in acutely ill medical patients
    Ajay K Kakkar
    Thrombosis Research Institute and University College London, London, United Kingdom
    N Engl J Med 365:2463-72. 2011
    ..Although thromboprophylaxis reduces the incidence of venous thromboembolism in acutely ill medical patients, an associated reduction in the rate of death from any cause has not been shown...
  14. doi request reprint International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)
    Ajay K Kakkar
    Thrombosis Research Institute, London, United Kingdom
    Am Heart J 163:13-19.e1. 2012
    ..The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke...
  15. pmc Antithrombotic therapy and survival in patients with malignant disease
    A K Kakkar
    Thrombosis Research Institute and Queen Mary University of London, Emmanuel Kaye Building Manresa Road, London SW3 6LR, UK
    Br J Cancer 102:S24-9. 2010
    ..This paper includes a summary of the data presented at the meeting and explores potential mechanisms by which antithrombotic agents might exert antitumour effects. The summary is followed by a consensus statement developed by the group...
  16. pmc Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry
    Ajay K Kakkar
    Thrombosis Research Institute, London, United Kingdom University College London, London, United Kingdom
    PLoS ONE 8:e63479. 2013
    ..The aim of this study was to describe the baseline characteristics and initial therapeutic management of patients with non-valvular atrial fibrillation across the spectrum of sites at which these patients are treated...
  17. ncbi request reprint Thrombosis and cancer
    Ajay K Kakkar
    Department of Surgical Oncology and Technology Imperial College, Hammersmith Hospital, London, UK
    Hematol J 5:S20-3. 2004
    ..Beyond their uses in the prevention and treatment of thrombosis, low-molecular-weight heparins have recently been shown to prolong survival in patients with solid tumour malignancy...
  18. doi request reprint Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
    Alexander T Cohen
    King s College Hospital, London, UK
    Lancet 371:387-94. 2008
    ....
  19. ncbi request reprint Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality
    Alexander T Cohen
    Vascular Medicine, Department of Surgery, King s College Hospital, London, SE5 9RS, UK
    Thromb Haemost 98:756-64. 2007
    ..Given the availability of effective VTE prophylaxis, many of these events and deaths could have been prevented. These results have important implications for the allocation of healthcare resources...
  20. ncbi request reprint Venous thrombosis in cancer patients: insights from the FRONTLINE survey
    Ajay K Kakkar
    Department of Surgical Oncology and Technology, Imperial College, London, United Kingdom
    Oncologist 8:381-8. 2003
    ....
  21. ncbi request reprint Low-molecular-weight heparins: beyond thrombosis in the management of the cancer patient
    Ajay K Kakkar
    Department of Surgical Oncology and Technology, Imperial College, Hammersmith Hospital, London, W12 0NN, United Kingdom
    Semin Thromb Hemost 29:13-5. 2003
    ..These, in turn, mediate several cellular events resulting in important phenotypic alterations in tumor cell behavior...
  22. ncbi request reprint Treatment of venous thromboembolism in cancer patients
    Gloria A Petralia
    Centre for Surgical Science, Barts and The London Queen Mary s School of Medicine and Dentistry, London, United Kingdom
    Semin Thromb Hemost 33:707-11. 2007
    ..These studies indicate that LMWH is associated with a lower rate for recurrent VTE and similar rates of bleeding when compared with oral anticoagulant therapy. Chronic exposure to LMWH may also prolong survival of cancer patients...
  23. doi request reprint Venous thromboembolism prophylaxis for the general surgical patient: where do we stand?
    Gloria A Petralia
    Centre for Surgical Sciences, Barts and The London Queen Mary s School of Medicine and Dentistry, London, UK
    Semin Respir Crit Care Med 29:83-9. 2008
    ..Guidelines are intended to assist surgeons in making decisions in regard to DVT prophylaxis when performing surgical procedures...
  24. ncbi request reprint Antithrombotic therapy with low molecular weight heparin in cancer patients
    P Petralia
    Department of Surgical Oncology and Technology, Imperial College, Hammersmith Hospital, Du Cane Road, W12 0NN, London, UK
    Eur J Med Res 9:119-24. 2004
    ..Beyond these well established uses for LMWH in the prevention and treatment of thrombosis in cancer patients, contemporary studies have demonstrated that LMWH therapy can prolong survival in patients with solid tumour malignant disease...
  25. ncbi request reprint Low- and ultra-low-molecular-weight heparins
    Ajay K Kakkar
    Department of Surgical Oncology and Technology, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Best Pract Res Clin Haematol 17:77-87. 2004
    ..More recently, a variety of heparin-like drugs have been evaluated as potential antithrombotic agents, and the synthetic pentasaccharide (fondaparinux) has been developed and evaluated for the prevention and treatment of VTE...
  26. ncbi request reprint Can low-molecular-weight heparins improve outcome in patients with cancer?
    Paul Thodiyil
    Department of Surgical Oncology and Technology, London, UK
    Cancer Treat Rev 28:151-5. 2002
    ..A prospective trial to investigate the effect of long-term treatment with the LMWH dalteparin on survival of patients with advanced cancer is currently being evaluated...
  27. ncbi request reprint Venous thromboembolism prophylaxis and treatment in patients with cancer
    Ajay K Kakkar
    Barts and the London School of Medicine and Dentistry, Queen Mary College, University of London, St Bartholomew s Hospital, London, UK
    Clin Adv Hematol Oncol 6:416-7. 2008
  28. ncbi request reprint Venous thromboembolism in laparoscopic surgery
    Dimitris Zacharoulis
    Department of Surgical Oncology and Technology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, UK
    Curr Opin Pulm Med 9:356-61. 2003
    ..The authors recommend that the use of standard prophylactic regimens tailored to specific patient populations for conventional operations be adopted for laparoscopic surgery until prospective data are available...
  29. ncbi request reprint High affinity binding of heparin by necrotic tumour cells neutralises anticoagulant activity--implications for cancer related thromboembolism and heparin therapy
    S Morita
    Thrombosis Research Institute, London, UK
    Thromb Haemost 86:616-22. 2001
    ..The findings also suggest a reason for the reported advantage of LMWH over UFH in treating venous thromboembolism in cancer patients and in improving patient survival...
  30. ncbi request reprint Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism
    Jeremy L Ockrim
    Department of Surgical Oncology and Technology, Imperial College and Hammersmith Hospitals NHS Trust, London, United Kingdom
    J Urol 174:527-33; discussion 532-3. 2005
    ..Here we report the influence of transdermal estradiol therapy on the coagulation profile of men with advanced prostate cancer...
  31. doi request reprint Antithrombotic therapy and survival in cancer patients
    A K Kakkar
    Barts and the London School of Medicine and Dentistry, Thrombosis Research Institute, London, UK
    Best Pract Res Clin Haematol 22:147-51. 2009
    ..Ongoing studies, with careful attention to distribution of prognostic variables for cancer outcome, will help to answer the question regarding whether LMWH may indeed be used for this indication...
  32. ncbi request reprint Thromboprophylaxis in the cancer patient
    P A Thodiyil
    Department of Surgery, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NS, UK
    Acta Haematol 106:73-80. 2001
    ..The principal role for vena cava filters is on occasions where recurrent thrombosis or haemorrhage complicates anticoagulation...
  33. ncbi request reprint Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use
    O E Dahl
    International Surgical Thrombosis Forum, Thrombosis Research Institute, London, UK
    Int Angiol 27:60-7. 2008
    ..In this paper, the International Surgical Thrombosis Forum proposes a strategy for the clinical investigation of new pharmacological agents for the prophylaxis of postoperative thrombotic events...
  34. ncbi request reprint Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines
    A K Kakkar
    Imperial College School of Medicine, Hammersmith Hospital, London, UK
    J Thromb Haemost 2:221-7. 2004
    ....
  35. ncbi request reprint Thromboembolism in brain tumors
    D C Walsh
    Department of Surgical Oncology, Technology and Intensive Care, Imperial College School of Medicine, Hammersmith Hospital, London W12 0SH, UK
    Curr Opin Pulm Med 7:326-31. 2001
    ..Antithrombotic therapy may also offer advantages over intracaval devices in prevention of secondary pulmonary embolism in patients with brain tumors...
  36. ncbi request reprint The role of the coagulation system in tumour angiogenesis
    G F Nash
    Hammersmith Hospital, London, UK
    Lancet Oncol 2:608-13. 2001
    ..We focus upon the contributions of the vascular endothelium, platelets, and coagulation factors to the angiogenic process and explore the coagulation system as a therapeutic target...
  37. ncbi request reprint Coagulation proteases and human cancer
    M T Sampson
    Department of Surgical Oncology and Technology, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, U K
    Biochem Soc Trans 30:201-7. 2002
    ..These proteases act via protease-activated receptors and tissue factor to alter gene expression, thereby modulating tumour cell growth, invasion, metastasis and angiogenesis...
  38. ncbi request reprint Platelets and cancer
    G F Nash
    Imperial College, Hammersmith Hospital, London, UK
    Lancet Oncol 3:425-30. 2002
    ..The assistance of platelets in cancer spread may provide opportunities to interrupt this relation, thus inhibiting metastasis...
  39. ncbi request reprint Venous thromboembolism and cancer
    David Bergqvist
    Uppsala University Hospital, Department of Surgical Sciences, Uppsala, Sweden
    Curr Probl Surg 44:157-216. 2007
  40. ncbi request reprint Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study
    Giancarlo Agnelli
    Division of Internal and Cardiovascular Medicine, University of Perugia, Ospedale S Maria della Misericordia, Perugia, Italy
    Circulation 116:180-7. 2007
    ..Rivaroxaban (BAY 59-7939) is an oral direct factor Xa inhibitor currently under clinical development...
  41. ncbi request reprint Mechanisms of disease: the impact of antithrombotic therapy in cancer patients
    Gloria A Petralia
    Clinical Trials Centre for Surgical Sciences, Barts and the London School of Medicine, UK
    Nat Clin Pract Oncol 2:356-63. 2005
    ....
  42. ncbi request reprint Thromboprophylaxis
    Daniel C Walsh
    J Neurosurg 96:806-7; author reply 807. 2002
  43. ncbi request reprint Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies
    William D Fisher
    McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4, Canada
    Thromb Haemost 97:931-7. 2007
    ..Overall, rivaroxaban total daily doses of 5-20 mg had the most favorable balance of efficacy and safety, relative to enoxaparin, for the prevention of VTE after major orthopaedic surgery...
  44. ncbi request reprint Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
    Agnes Y Y Lee
    Department of Medicine, McMaster University, Hamilton, Ont, Canada
    N Engl J Med 349:146-53. 2003
    ..We compared the efficacy of a low-molecular-weight heparin with that of an oral anticoagulant agent in preventing recurrent thrombosis in patients with cancer...
  45. ncbi request reprint Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technical University of Munich, Germany
    Thromb Haemost 94:814-9. 2005
    ....
  46. ncbi request reprint A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
    Bengt I Eriksson
    Department of Orthopaedics, Sahlgrenska University Hospital Ostra, SE 416 85 Gothenburg, Sweden
    Circulation 114:2374-81. 2006
    ..Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--could be an alternative to heparins and warfarin for the prevention and treatment of thromboembolic disorders...
  47. ncbi request reprint Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
    Wolfgang Mueck
    Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
    Thromb Haemost 100:453-61. 2008
    ....
  48. ncbi request reprint Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism
    Agnes Y Y Lee
    Hamilton Health Science, Henderson Hospital, Room 9, 90 Wing, 711 Concession St, Hamilton, ON L8V 1C3, Canada
    J Clin Oncol 23:2123-9. 2005
    ..We investigated the influence of a low molecular weight heparin dalteparin on the survival of patients with active cancer and acute venous thromboembolism...
  49. doi request reprint Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
    Bengt I Eriksson
    Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    N Engl J Med 358:2765-75. 2008
    ..This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty...
  50. ncbi request reprint Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement
    Bengt I Eriksson
    Department of Orthopaedics, Sahlgrenska University Hospital Ostra, SU Ostra sjukhuset, SE 41685 Goteborg, Sweden
    Thromb Res 120:685-93. 2007
    ..Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in clinical development for the prevention of thromboembolic disorders. The aim of this study was to demonstrate proof-of-principle for rivaroxaban...
  51. ncbi request reprint Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery
    Wolfgang Mueck
    Clinical Pharmacology, Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
    Clin Pharmacokinet 47:203-16. 2008
    ....
  52. ncbi request reprint Current status of pulmonary embolism in general surgery in Japan
    Masato Sakon
    Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan
    Surg Today 34:805-10. 2004
    ..Perioperative prophylaxis against venous thromboembolism is important, but its benefits need to be confirmed by prospective clinical studies...
  53. ncbi request reprint Contaminated heparin
    Ajay K Kakkar
    N Engl J Med 359:1292-3; author reply 1293. 2008